Huawei Hengyuan is a biomedical technology enterprise, dedicated to using cell reprogramming technology to prepare Sertoli cells (with immune immunity function) in vitro, mainly used in: autoimmune diseases (such as rheumatoid arthritis); reproductive assistance therapy; human body Chronic disease (eg Parkinson’s); organ/tissue transplantation (eg skin allograft). Recently, Huawei Hengyuan completed tens of millions of Pre-A+ rounds of financing. This round of financing was led by Danlu Capital, followed by new shareholders such as Ruisheng Investment and Yuanhe Capital. It is reported that the funds raised in this round will be mainly used for the safety verification, process development and clinical declaration of Huawei Hengyuan’s core pipeline, the expansion of subsequent production bases and the recruitment of talents.
This article is transferred from: https://www.itjuzi.com/investevent/13699006
This site is only for collection, and the copyright belongs to the original author.